Literature DB >> 30670267

Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials.

Jessie Hawkins1, Colby Baker2, Lindsey Cherry2, Elizabeth Dunne2.   

Abstract

Upper respiratory symptoms are often treated with over the counter drugs, antibiotics, and antiviral medications. Due to concerns about safety and efficacy, there is a demand for an alternative solution. Black elderberry (Sambucus nigra) has been used to treat cold and flu symptoms, but there are no large-scale studies or meta-analyses. This meta-analysis quantifies the effects of elderberry supplementation and evaluates moderators including vaccination status and the underlying pathology. This analysis included a total of 180 participants and evaluates moderators such as vaccination status and cause of the upper respiratory symptoms. Supplementation with elderberry was found to substantially reduce upper respiratory symptoms. The quantitative synthesis of the effects yielded a large mean effect size. These findings present an alternative to antibiotic misuse for upper respiratory symptoms due to viral infections, and a potentially safer alternative to prescription drugs for routine cases of the common cold and influenza.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Common cold; Elderberry; Influenza; Sambucus

Mesh:

Substances:

Year:  2018        PMID: 30670267     DOI: 10.1016/j.ctim.2018.12.004

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  18 in total

1.  A Pragmatic Approach to Immunity & Respiratory Viral Infections.

Authors:  Todd A Born
Journal:  Integr Med (Encinitas)       Date:  2020-10

Review 2.  COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Authors:  Dâmaris Silveira; Jose Maria Prieto-Garcia; Fabio Boylan; Omar Estrada; Yris Maria Fonseca-Bazzo; Claudia Masrouah Jamal; Pérola Oliveira Magalhães; Edson Oliveira Pereira; Michal Tomczyk; Michael Heinrich
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

Review 3.  Natural Supplements for COVID19-Background, Rationale, and Clinical Trials.

Authors:  Melody Hermel; Megan Sweeney; Yu-Ming Ni; Robert Bonakdar; Douglas Triffon; Christopher Suhar; Sandeep Mehta; Sarah Dalhoumi; James Gray
Journal:  J Evid Based Integr Med       Date:  2021 Jan-Dec

Review 4.  Health benefits of cyanidin-3-glucoside as a potent modulator of Nrf2-mediated oxidative stress.

Authors:  Sofia Rahman; Shimy Mathew; Pooja Nair; Wafaa S Ramadan; Cijo George Vazhappilly
Journal:  Inflammopharmacology       Date:  2021-03-19       Impact factor: 4.473

5.  Native and exotic plants with edible fleshy fruits utilized in Patagonia and their role as sources of local functional foods.

Authors:  Melina Fernanda Chamorro; Ana Ladio
Journal:  BMC Complement Med Ther       Date:  2020-05-24

6.  Phytotherapic compounds against coronaviruses: Possible streams for future research.

Authors:  Michele Antonelli; Davide Donelli; Valentina Maggini; Fabio Firenzuoli
Journal:  Phytother Res       Date:  2020-05-10       Impact factor: 5.878

7.  Anti-Influenza with Green Tea Catechins: A Systematic Review and Meta-Analysis.

Authors:  Anchalee Rawangkan; Kirati Kengkla; Sukrit Kanchanasurakit; Acharaporn Duangjai; Surasak Saokaew
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

8.  Evaluation of toxicity of Bilsaan stem bark extracts in Swiss Albino mice.

Authors:  Faris Alrumaihi
Journal:  Int J Health Sci (Qassim)       Date:  2019 Sep-Oct

Review 9.  Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view.

Authors:  Andreas Kronbichler; Maria Effenberger; Michael Eisenhut; Keum Hwa Lee; Jae Il Shin
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

10.  Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.

Authors:  Mark F McCarty; James J DiNicolantonio
Journal:  Prog Cardiovasc Dis       Date:  2020-02-12       Impact factor: 8.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.